Dr David Epstein
joined the faculty and leadership at Duke-NUS Graduate Medical School, Singapore, in early 2013. Currently, he is Director of Duke-NUS’s Centre for Technology & Development (CTeD), the aim of which is to advance healthcare innovations derived through commercialisation of Duke-NUS intellectual property. His work within CTeD focuses on entrepreneurship and developing novel models of value creation and value capture. He is particularly interested in enabling a sustainable biomedical ecosystem in Singapore through innovation and improvements in healthcare delivery. In 2014, he was named the founding Director of Singapore’s National Health Innovation Centre (NHIC) which is funded and overseen by the National Medical Research Council (NMRC) with the aim of providing the clinical research sector long-term financial support and strategic guidance related to innovation and commercialisation. Dr Epstein is Associate Professor in the Cancer & Stem Cell Biology Programme, where his research focuses on mechanisms of oncogene activation through alternative splicing. Dr Epstein is Associate Dean of Research for the medical school.
Prior to joining the faculty and Office of Research at Duke-NUS, Dr Epstein was the New York Site-Head, Senior Vice President and Chief Scientific Officer for Oncology Research at OSI Pharmaceuticals, where he was responsible for cancer drug discovery and translational science. He was a principal founder and Vice President of Archemix Corp., an aptamer therapeutics biotechnology company in Cambridge, Massachusetts, from 2001-2006.
Dr Epstein has over 15 years of R&D leadership experience in both the pharmaceutical and biotechnology industries. He also headed programmes in oncology translational sciences and clinical biomarker discovery & development which encompassed five separate therapeutic agents in clinical development.